Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 6/20 | 0.55 |
| ▸ | HTR2A | P28223 | 6/20 | 0.42 |
| ▸ | HRH1 | P35367 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11525800 | 0.85 | HTR2A (0.52) | ANPEPHTR2AHRH1HTR2CHDAC4 | |
| SCHEMBL30767843 | 0.82 | ANPEP (0.53) | ANPEPHTR2AHRH1HTR2CCYP1A2 | |
| SCHEMBL13176963 | 0.78 | HTR2A (0.41) | ANPEPHTR2AHRH1HTR2CHDAC4 | |
| SCHEMBL7127466 | 0.77 | ANPEP (0.61) | ANPEPHTR2AHRH1HTR2CCYP1A2 | |
| SCHEMBL2601579 | 0.77 | ACP3 (0.48) | HTR2AHTR2CCYP1A2 | |
| SCHEMBL29038267 | 0.73 | MAOB (0.39) | ANPEPHTR2AHRH1HTR2CCYP1A2 | |
| SCHEMBL28902065 | 0.72 | HTR2A (0.40) | ANPEPHTR2AHRH1HTR2CHDAC4 | |
| SCHEMBL28428106 | 0.72 | MAOB (0.41) | ANPEPHTR2AHRH1HTR2CCYP1A2 | |
| SCHEMBL8036318 | 0.72 | ANPEP (0.50) | ANPEPHTR2AHRH1HTR2CCYP1A2 | |
| SCHEMBL7385396 | 0.71 | ANPEP (0.59) | ANPEPHTR2AHRH1HTR2CCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150975-A1 | COMPOUNDS USED AS KINASE INHIBITORS AND APPLICATION THEREOF | TYK MEDICINES (ZHENGZHOU), INC. (CN) | 2023-05-18 | — | — | US | disclosed |
| US-20230150975-A1 | COMPOUNDS USED AS KINASE INHIBITORS AND APPLICATION THEREOF | TYK MEDICINES (ZHENGZHOU), INC. (CN) | 2023-05-18 | — | — | US | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150975-A1 | COMPOUNDS USED AS KINASE INHIBITORS AND APPLICATION THEREOF | EGFR, ERBB2, ERBB3 | ANPEP 564/4885HTR2A 3390/4885HRH1 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.